Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Sell
RSI(14)
33.246
Neutral
STOCH(KDJ)(9,3,3)
36.577
Sell
ATR(14)
0.110
High Vlolatility
CCI(14)
-134.531
Sell
Williams %R
94.118
Oversold
TRIX(12,20)
-0.987
Sell
StochRSI(14)
0.000
Sell
Marker Therapeutics Inc
MRKR0.950USD
-0.050-5.00%
Market hours （ET）Quotes delayed by 15 min
10.73MMarket Cap
LossP/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-26Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a strong stock market performance and outperforming fundamentals, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
3
analysts
Buy
Current Rating
8.167
Target Price
+548.15%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 87.59% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.59M.
Overvalued
The company’s latest PE is -0.74, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.08M shares, decreasing 10.56% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 275.35K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.42.
Financial Health
Currency: USD Updated：2025-08-26The company's current financial score is 7.08, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 349.10K, representing a year-over-year decrease of 71.94%, while its net profit experienced a year-over-year decrease of 85.81%.
Score
Financials
10.00
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.35
Operational Efficiency
3.85
Growth Potential
7.15
Shareholder Returns
7.06
Valuation Dimension
Currency: USD Updated：2025-08-26The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -0.74, which is 31.13% below the recent high of -0.97 and -371.76% above the recent low of -3.48.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 166/690
No Data
Forecast
Currency: USD Updated：2025-08-26The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Marker Therapeutics Inc is 8.00, with a high of 12.50 and a low of 4.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.167
Target Price
+548.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Marker Therapeutics Inc
MRKR
3
CRISPR Therapeutics AG
CRSP
29
Ionis Pharmaceuticals Inc
IONS
27
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-26The company’s current price momentum score is 5.68, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 1.34 and the support level at 0.82, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.184
Sell
MA10
1.206
Sell
MA20
1.239
Sell
MA50
1.436
Sell
MA100
1.343
Sell
MA200
1.919
Sell
Institutional Confidence
Currency: USD Updated：2025-08-26The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 44.86%, representing a quarter-over-quarter decrease of 2.18%. The largest institutional shareholder is The Vanguard, holding a total of 275.35K shares, representing 2.13% of shares outstanding, with 6.28% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
New Enterprise Associates (NEA)
Wilson (John Robert)
Blue Owl Capital Holdings LP
Aisling Capital Management LP
Vera (Juan F. M.D.)
Alyeska Investment Group, L.P.
Geode Capital Management, L.L.C.
LPL Financial LLC
1
2
Risk Assessment
Currency: USD Updated：2025-08-26The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.03, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.55
VaR
+9.23%
240-Day Maximum Drawdown
+79.42%
240-Day Volatility
+144.10%
Return
Best Daily Return
60 days
+29.00%
120 days
+33.04%
5 years
+51.27%
Worst Daily Return
60 days
-20.63%
120 days
-20.63%
5 years
-93.67%
Sharpe Ratio
60 days
-0.09
120 days
-0.02
5 years
+0.21
Risk Assessment
Maximum Drawdown
240 days
+79.42%
3 years
+88.61%
5 years
+98.01%
Return-to-Drawdown Ratio
240 days
-0.79
3 years
-0.25
5 years
-0.19
Skewness
240 days
+1.03
3 years
+1.18
5 years
-0.56
Volatility
Realised Volatility
240 days
+144.10%
5 years
+130.71%
Standardised True Range
240 days
+25.47%
5 years
+65.68%
Downside Risk-Adjusted Return
120 days
-4.14%
240 days
-4.14%
Maximum Daily Upside Volatility
60 days
+313.25%
Maximum Daily Downside Volatility
60 days
+92.81%
Liquidity
Average Turnover Rate
60 days
+15.30%
120 days
+8.26%
5 years
--
Turnover Deviation
20 days
-42.14%
60 days
+525.62%
120 days
+237.68%
Peers
Currency: USD Updated：2025-08-26Marker Therapeutics Inc
MRKR
5.42 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Zoetis Inc
ZTS
7.55 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.53 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.51 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
ACADIA Pharmaceuticals Inc
ACAD
7.45 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
